The estimated Net Worth of Richard Hague is at least $1.22 Millón dollars as of 9 August 2021. Mr Hague owns over 10,208 units of PolarityTE Inc stock worth over $195,390 and over the last 9 years he sold PTE stock worth over $374,757. In addition, he makes $649,256 as Pres & CEO at PolarityTE Inc.
Mr has made over 8 trades of the PolarityTE Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 10,208 units of PTE stock worth $8,473 on 9 August 2021.
The largest trade he's ever made was selling 12,950 units of PolarityTE Inc stock on 7 February 2020 worth over $39,109. On average, Mr trades about 1,303 units every 31 days since 2015. As of 9 August 2021 he still owns at least 814,123 units of PolarityTE Inc stock.
You can see the complete history of Mr Hague stock trades at the bottom of the page.
Richard Hague is the Pres & CEO at PolarityTE Inc.
As the Pres & CEO of PolarityTE Inc, the total compensation of Mr Hague at PolarityTE Inc is $649,256. There are no executives at PolarityTE Inc getting paid more.
Mr Hague is 61, he's been the Pres & CEO of PolarityTE Inc since . There are 1 older and 3 younger executives at PolarityTE Inc. The oldest executive at PolarityTE Inc is Dr. Stephen Milner M.D., DDS, DSc, FRCSE, FACS, 72, who is the Chief Clinical Officer & Member of Clinical Advisory Board.
Richard's mailing address filed with the SEC is 32 Wiggins Ave, Bedford, MA 01730, USA.
Over the last 6 years, insiders at PolarityTE Inc have traded over $998,958 worth of PolarityTE Inc stock and bought 381,180 units worth $1,230,731 . The most active insiders traders include Steve Gorlin, Peter A Cohen y Paul Elliot Mann. On average, PolarityTE Inc executives and independent directors trade stock every 21 days with the average trade being worth of $3,753. The most recent stock trade was executed by Chris Nolet on 12 January 2023, trading 36,497 units of PTE stock currently worth $8,759.
polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™
PolarityTE Inc executives and other stock owners filed with the SEC include: